Comparative Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors on Sepsis in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
Key claim: In patients with chronic obstructive pulmonary disease and type 2 diabetes, GLP-1 receptor agonists were associated with significantly lower risks of sepsis, pneumonia, and all-cause mortality compared with DPP-4 inhibitors.
Abstract
BACKGROUND: Sepsis is a major cause of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). Antihyperglycemic agents may influence infection risk through distinct immunometabolic pathways. We compared glucagon-like peptide-1 receptor agonists (GLP-1RAs) with dipeptidyl peptidase-4 inhibitors (DPP-4is) in patients with COPD and type 2 diabetes mellitus (T2DM). METHODS: This population-based, active-comparator, new-user cohort study used the TriNetX Global Network. Adults aged 40-100 years with COPD and T2DM who initiated a GLP-1RA or DPP-4i between 2007 and 2019 were included. Propensity score matching (1:1) adjusted for demographics, BMI, HbA1c, COPD severity proxies, comorbidities, and medications. The primary outcome was sepsis; secondary outcomes were pneumonia, severe sepsis, and all-cause mortality, assessed at 1, 3, 6, 12, and 24 months. RESULTS: Before matching, 21,622 patients started a GLP-1RA and 67,259 a DPP-4i; after matching, 20,074 remained in each group with balanced characteristics (all standardized mean differences <0.10). Compared with DPP-4i users, GLP-1RA users had a significantly lower risk of sepsis at 1 year (hazard ratio [HR] 0.852; 95% confidence interval [CI] 0.770-0.942). The risks of secondary outcomes at 1 year were numerically lower in the GLP-1RA group, with statistically significant reductions in pneumonia (HR 0.729; 95% CI 0.671-0.792) and all-cause mortality (HR 0.656; 95% CI 0.587-0.732), while the association with severe sepsis did not reach statistical significance (HR 0.891; 95% CI 0.770-1.033). CONCLUSION: In patients with COPD and T2DM, initiation of GLP-1RAs was associated with lower risks of sepsis, pneumonia, and all-cause mortality compared with DPP-4is. However, given the observational design, causality cannot be established and residual confounding remains a potential limitation. While these findings suggest potential benefits of GLP-1RAs beyond glycemic control, further confirmation through randomized controlled trials is warranted to guide clinical decision-making.
Why this matters
[human-observational] This cohort extends the GLP-1 receptor agonist outcome record to serious infections and mortality in patients with both COPD and type 2 diabetes, using DPP-4 inhibitors as an active comparator. [human-observational] Propensity matching does not eliminate residual confounding, so the associations do not establish infection prevention or a general anti-aging effect.